Welcome to our dedicated page for Tyra Biosciences SEC filings (Ticker: TYRA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Tyra Biosciences, Inc. (Nasdaq: TYRA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Tyra Biosciences is a clinical-stage biotechnology company based in Carlsbad, California that focuses on developing precision medicines targeting FGFR biology through its in-house SNÅP platform. Its SEC filings give investors structured insight into how the company reports its financial condition, pipeline progress and material events related to its FGFR-focused programs.
Among the key documents, Form 8-K current reports are used by Tyra to announce material events such as quarterly financial results and significant clinical milestones. For example, recent 8-K filings reference press releases reporting second and third quarter financial results and an 8-K dated June 30, 2025 describing the first patient dosed in the SURF302 Phase 2 study of TYRA-300 (dabogratinib) in intermediate risk non-muscle invasive bladder cancer. These filings often incorporate press releases by reference, linking financial metrics with updates on studies like SURF302, BEACH301, SURF301, SURF201 and SURF431.
Investors can also use Tyra’s periodic reports (such as the annual report on Form 10-K and subsequent filings referenced in forward-looking statement sections) to understand risk factors, research and development priorities, and the status of clinical-stage candidates including dabogratinib, TYRA-200 and TYRA-430. The company’s filings discuss topics such as trial design, anticipated data readouts, dependence on third parties, regulatory interactions and intellectual property considerations.
On Stock Titan, these SEC filings are complemented by AI-powered summaries that help explain complex sections, highlight key disclosures and point out items of interest such as clinical trial milestones, cash runway commentary and forward-looking statements tied to the SNÅP platform and FGFR-targeted pipeline. Users can quickly review newly posted 8-Ks, 10-Ks and other forms, and connect them to Tyra’s broader narrative in precision oncology and genetically defined skeletal dysplasias.
Tyra Biosciences, Inc. filed an initial insider report for Yuliya Rueb, Vice President, Finance (PAO), outlining her existing stock option holdings. The filing lists several options to buy common stock with exercise prices ranging from $6.50 to $21.57 per share and expirations between 2032 and 2035.
Each grant vests over time. One option began vesting on October 18, 2023 with 25% vested then and the remainder vesting monthly. Other grants vest in 48 monthly installments following commencement dates in July 2024, August 2024, and August 2025, conditioned on her continued service.
Tyra Biosciences, Inc. named Julia Rueb, its Vice President of Finance, as the company’s principal accounting officer, effective April 1, 2026. She succeeds Chief Financial Officer Alan Fuhrman in this specific role, while he continues to serve as the company’s principal financial officer.
Rueb, age 40, has been Vice President, Finance since January 2024 and previously held senior accounting and controller roles at the company. Her background includes technical accounting and consulting positions at SOAProjects, van den Boom & Associates, and audit experience at Ernst & Young, primarily serving public life sciences companies.
Tyra Biosciences director Gilla Kaplan reported option exercises and related share dispositions. Kaplan exercised stock options to acquire a total of 67,467 shares of common stock at an exercise price of $2.25 per share on March 25–26, 2026.
On March 25, 2026, Kaplan acquired 14,295 shares via option exercise and sold 14,295 shares of common stock in open-market transactions at a weighted average price of $36.9714 per share, with individual sale prices ranging from $36.95 to $37.11. On March 26, 2026, Kaplan exercised options for 53,172 shares and disposed of 53,172 shares back to the issuer at $37.7483 per share.
Following these transactions, Kaplan directly owned 28,231 shares of Tyra Biosciences common stock. The exercised options were reported as fully vested, and there are no remaining derivative positions shown in this filing.
TYRA proposed sale of 53,172 common shares via stock option exercise. The filing lists 53,172 shares to be sold on 03/26/2026 through a stock option exercise for cash to the issuer. The filing also shows 14,295 shares sold in the prior three months on 03/25/2026.
Tyra Biosciences, Inc. Chief Financial Officer Alan Fuhrman increased his holdings through the company’s employee stock purchase plan. On March 13, 2026, he acquired 1,376 shares of common stock at $9.129 per share under the 2021 Employee Stock Purchase Plan. After this ESPP acquisition, he directly owns 16,164 common shares, reflecting a routine, compensation-related increase rather than an open-market purchase.
Tyra Biosciences President and CEO Harris Todd increased his direct holdings through a compensation-related share acquisition. On March 13, 2026, he acquired 1,463 shares of Tyra Biosciences common stock at $9.129 per share under the company’s 2021 Employee Stock Purchase Plan.
After this transaction, Todd directly owns 1,358,631 common shares. This was a grant/award-type acquisition under an employee plan, not an open-market purchase, and represents a small addition relative to his existing stake.
TYRA reported Rule 144 sale notices showing an insider sold blocks of common stock. The filing lists three transactions of 8,000 shares each on 12/12/2025, 01/12/2026, and 02/12/2026. The filing also shows 53,372,098 shares outstanding as of 03/12/2026.
Tyra Biosciences, Inc. received an updated Schedule 13D/A showing RA Capital’s group now beneficially owns 12,266,575 shares of common stock, or 21.2% of the company.
The filing states this change results from dilution of their stake after additional Tyra shares were issued, rather than new buying or selling by the RA Capital entities.
The ownership includes shares held by RA Capital Healthcare Fund, a separately managed account, RA Capital Nexus Fund, and stock options and warrants tied to RA Capital, some of which are subject to a 19.99% beneficial ownership blocker that currently prevents further warrant exercises.
Tyra Biosciences, Inc. entered into an agreement to issue and sell 4,000,000 shares of common stock to a large investment management firm in a block transaction. The shares are priced at $31.50 per share, and Tyra Biosciences expects to receive $126.0 million in gross proceeds upon settlement, before fees and other expenses.
The transaction is being carried out under the company’s existing “at-the-market” offering program, which is registered on Form S-3 under the Securities Act of 1933. The terms of this program are described in a sales agreement prospectus dated May 16, 2025, with related documents available on the SEC’s website.